WHAT WE DO
NanoMedTrix is developing game-changing, multi-modal nanoparticle contrast agents with the goal of revolutionizing medical diagnostics through non-invasive targeted imaging and therapeutic interventions. Potential clinical applications include the early, safe and accurate detection of diseases such as bladder cancer and colorectal cancer. Early detection of these cancers dramatically improves patient outcomes, and significantly reduces the financial costs associated with their treatment. In addition to these and other clinical applications, our contrast agents will also provide the research community with a valuable tool in areas such as regenerative technology and targeted radiology.

OUR COMPANY
NanoMedTrix was formed in August of 2012, and since then has been awarded funding by the State of Iowa (as recipients of the inaugural Demonstration Fund Award and the first SBIR/STTR Outreach Program Award), as well as the University of Iowa. The company has recently acquired new facilities at the BioVentures Center in the University of Iowa Research Park, located in Coralville, where 785 square feet of wet lab space is being set up for commercial production/manufacturing of our contrast agents. Simultaneously, laboratory work is underway to enhance and refine our contrast agents preparatory to scaling up production to commercial levels. Surface and core chemistry modifications are being made to accommodate specific targeting and provide a solution for clinical interventions.

OUR PRODUCTS
We have developed research-based contrast agents with unique features that will make them invaluable in both pre-clinical and clinical settings. In addition to being multi-modal, they are also multi-scale, being effective at the level of the molecule, cell, tissue and organ. They are also capable of flagging specific tissues or pathologies and have the potential for use in targeted radiology and therapeutic interventions.
OUR PARTNERSHIPS

We enjoy a number of successful collaborations with University of Iowa Hospitals and Clinics and with the Carver College of Medicine, specifically with researchers in Urology, Gastroenterology and Pathology, with whom we are working towards the early detection and eradication of bladder cancer, colorectal cancer and liver cancer respectively.